组蛋白去乙酰化酶(HDACs)在胃癌中的研究进展
The Relationship between Histone Deacetylase (HDACs) and Gastric Cancer
DOI: 10.12677/ACM.2020.109320, PDF,   
作者: 徐 珊, 尹晓燕, 田字彬：青岛大学附属医院消化内科，山东 青岛
关键词: 胃癌；组蛋白去乙酰化酶；表观遗传；Gastric Cancer； Histone Deacetylase； Epigenetic
摘要: 胃癌(gastric cancer, GC)是消化道常见肿瘤之一，早期诊断率低，多数患者出现临床症状就诊往往是GC发展的晚期，因此治疗效果不佳，转移风险高，预后差。近年国内外多个研究证实组蛋白去乙酰化酶(histone deacetylases, HDACs)在肿瘤进展中起着关键作用，通过改变组蛋白和非组蛋白的乙酰化来调控细胞周期、分化和凋亡，从而在肿瘤进展过程中破坏体内乙酰化动态平衡。GC的发生发展与HDACs表达失衡密切相关，然而它们在GC中的具体机制尚不清楚，本文主要对HDACs与GC的研究进行回顾和总结，以期为进一步研究提供参考，为临床治疗提供新作用靶点。
Abstract: Gastric cancer (GC) is one of the common malignant gastrointestinal tumors, with low early diagnosis rate. Most patients presenting clinical symptoms tend to be at the late stage of GC development, so this leads to a low cure rate, a high risk of metastasis, and a poor prognosis. In recent years, many researches in the domestic and foreign have confirmed that histone deacetylases (HDACs) play a critical role in tumor progression. HDACs regulate cell cycle, differentiation and apoptosis by changing the acetylation of histones and non-histones, thus disrupting the dynamic balance of acetylation in vivo during tumor progression. The occurrence and development of GC are closely related to the imbalance of HDACs expression. However, the specific role of HDACs in GC is still unclear. This article mainly reviews and summarizes the research on HDACs and GC, so as to provide reference for further research and provide a new target for clinical treatment.
文章引用：徐珊, 尹晓燕, 田字彬. 组蛋白去乙酰化酶(HDACs)在胃癌中的研究进展[J]. 临床医学进展, 2020, 10(9): 2127-2132. https://doi.org/10.12677/ACM.2020.109320

参考文献

[1] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Zhou, M., Wang, H., Zeng, X., Yin, P., Zhu, J., Chen, W., Li, X., Wang, L., Wang, L., Liu, Y., Liu, J., Zhang, M., Qi, J., Yu, S., Afshin, A., Gakidou, E., Glenn, S., Krish, V.S., Miller-Petrie, M.K., Mountjoy-Venning, W.C., Mullany, E.C, Redford S.B., Liu, H., Naghavi, M., Hay, S.I., Wang, L., Murray, C.J.L. and Liang, X. (2019) Mortality, Morbidity, and Risk Factors in China and Its Provinces, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet, 394, 1145-1158. [Google Scholar] [CrossRef] 
[3] Yang, W.Y., Gu, J.L. and Zhen, T.M. (2014) Recent Advances of Histone Modification in Gastric Cancer. Journal of Cancer Research and Therapeutics, 10, 240-245. [Google Scholar] [CrossRef] [PubMed]
[4] Padmanabhan, N., Ushijima, T. and Tan, P. (2017) How to Stomach an Epigenetic Insult: The Gastric Cancer Epigenome. Nature Reviews Gastroenterology & Hepatology, 14, 467-478. [Google Scholar] [CrossRef] [PubMed]
[5] Wang, G.G., Allis, C.D. and Chi, P. (2007) Chromatin Remodeling and Cancer, Part I: Covalent Histone Modifications. Trends in Molecular Medicine, 13, 363-372. [Google Scholar] [CrossRef] [PubMed]
[6] Fuchs, J., Demidov, D., Houben, A. and Schubert, I. (2006) Chromosomal Histone Modification Patterns--From Conservation to Diversity. Trends in Plant Science, 11, 199-208. [Google Scholar] [CrossRef] [PubMed]
[7] De Ruijter, A.J., Van Gennip, A.H., Caron, H.N., Kemp, S. and Van Kuilenburg, A.B. (2003), Histone Deacetylases (HDACs): Characterization of the Classical HDAC Family. The Biochemical Journal, 370, 737-749. [Google Scholar] [CrossRef] [PubMed]
[8] Shah, P., Gau, Y. and Sabnis, G. (2014) Histone Deacetylase Inhibitor Entinostat Reverses Epithelial to Mesenchymal Transition of Breast Cancer Cells by Reversing the Repression of E-Cadherin. Breast Cancer Research and Treatment, 143, 99-111. [Google Scholar] [CrossRef] [PubMed]
[9] Shi, J., Qu, Y.P. and Hou, P. (2014) Pathogenetic Mechanisms in Gastric Cancer. World Journal of Gastroenterology, 20, 13804-13819. [Google Scholar] [CrossRef] [PubMed]
[10] Smith, B.C. and Denu, J.M. (2009) Chemical Mechanisms of Histone Lysine and Arginine Modifications. Biochimica et Biophysica Acta, 1789, 45-57. [Google Scholar] [CrossRef] [PubMed]
[11] Hassell, K.N. (2019) Histone Deacetylases and Their Inhibitors in Cancer Epigenetics. Diseases, 7, 57. [Google Scholar] [CrossRef] [PubMed]
[12] Yang, X.J. and Seto, E. (2008) The Rpd3/Hda1 Family of Lysine Deacetylases: From Bacteria and Yeast to Mice and Men. Nature Reviews Molecular Cell Biology, 9, 206-218. [Google Scholar] [CrossRef] [PubMed]
[13] Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S., Yao, T., Hosoi, F., Basaki, Y., Ono, M., Kuwano, M., Tanaka, M. and Tsuneyoshi, M. (2007) Expression Profile of Class I Histone Deacetylases in Human Cancer Tissues. Oncology Reports, 18, 769-774. [Google Scholar] [CrossRef] 
[14] Mutze, K., Langer, R., Becker, K., Ott, K., Novotny, A., Luber, B., Hapfelmeier, A., Göttlicher, M., Höfler, H. and Keller, G. (2010) Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer. Annals of Surgical Oncology, 17, 3336-3343. [Google Scholar] [CrossRef] [PubMed]
[15] Orenay-Boyacioglu, S., Kasap, E., Gerceker, E., Yuceyar, H., Demirci, U., Bilgic, F. and Korkmaz, M. (2018) Expression Profiles of Histone Modification Genes in Gastric Cancer Progression. Molecular Biology Reports, 45, 2275-2282. [Google Scholar] [CrossRef] [PubMed]
[16] Jiang, Z.H., Yang, H.M., Zhang, X.Y., Wang, Z.D., Rong, R. and Wang, X.H. (2019) Histone Deacetylase-1 as a Prognostic Factor and Mediator of Gastric Cancer Progression by Enhancing Glycolysis. Human Pathology, 85, 194-201. [Google Scholar] [CrossRef] [PubMed]
[17] Xu, G.R., Zhu, H.X., Zhang, M.H. and Xu, J.H. (2018) Histone Deacetylase 3 Is Associated With Gastric Cancer Cell Growth Via the Mir-454-Mediated Targeting of CHD5. International Journal of Molecular Medicine, 41, 155-163. [Google Scholar] [CrossRef] [PubMed]
[18] Wang, Y., Xu, P., Yao, J., Yang, R.N., Shi, Z.G., Zhu, X.J., Feng, X.S. and Gao, S.G. (2016) Microrna-216b Is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8. Targeted Oncology, 11, 197-207. [Google Scholar] [CrossRef] [PubMed]
[19] Li, Y., Zhang, M.M., Dorfman, R.G., Pan, Y., Tang, D.H., Xu, L., Zhao, Z.G., Zhou, Q., Zhou, L.X., Wang, Y.M., Yin, Y.Y., Shen, S.S., Kong, B., Friess, H., Zhao, S.M., Wang, L. and Zou, X.P. (2018) SIRT2 Promotes the Migration and Invasion of Gastric Cancer through RAS/ERK/JNK/MMP-9 Pathway by Increasing PEPCK1-Related Metabolism. Neoplasia (New York, N.Y.), 20, 745-756. [Google Scholar] [CrossRef] [PubMed]
[20] Sun, H., Huang, D., Liu, G., Jian, F., Zhu, J. and Zhang, L. (2018) SIRT4 Acts as a Tumor Suppressor in Gastric Cancer by Inhibiting Cell Proliferation, Migration, and Invasion. Oncotargets and Therapy, 11, 3959-3968. [Google Scholar] [CrossRef] 
[21] Zhou, J.M., Wu, A., Yu, X.T., Zhu, J.M. and Dai, H. (2017) SIRT6 Inhibits Growth of Gastric Cancer by Inhibiting JAK2/STAT3 Pathway. Oncology Reports, 38, 1059-1066. [Google Scholar] [CrossRef] [PubMed]
[22] Lin, L.L., Jiang, H.P., Huang, M.K., Hou, X., Sun, X.P., Jiang, X., Dong, X.S., Sun, X.Y.., Zhou, B.G. and Qiao, H.Q. (2015) Depletion of Histone Deacetylase 1 Inhibits Metastatic Abilities of Gastric Cancer Cells by Regulating the Mir-34a/CD44 Pathway. Oncology Reports, 34, 663-672. [Google Scholar] [CrossRef] [PubMed]
[23] Kim, J.K., Noh, J.H., Eun, J.W., Jung, K.H., Bae, H.J., Shen, Q., Kim, M.G., Chang, Y.G., Kim, S.J., Park, W.S., Lee, J.Y., Borlak, J. and Nam, S.W. (2013) Targeted Inactivation of HDAC2 Restores P16ink4a Activity and Exerts Antitumor Effects on Human Gastric Cancer. Molecular Cancer Research, 11, 62-73. [Google Scholar] [CrossRef] 
[24] Ma, Y.M., Yue, Y.F., Pan, M., Sun, J., Chu, J., Lin, X.Y., Xu, W.X., Feng, L.F., Chen, Y., Chen, D.W., Shin, V.Y., Wang, X. and Jin, H.C. (2015) Histone Deacetylase 3 Inhibits New Tumor Suppressor Gene DTWD1 in Gastric Cancer. American Journal of Cancer Research, 5, 663-673.
[25] Spaety, M.E., Gries, A., Badie, A., Venkatasamy, A., Romain, B., Orvain, C., Yanagihara, K., Okamoto, K., Jung, A.C., Mellitzer, G., Pfeffer, S. and Gaiddon, C. (2019) HDAC4 Levels Control Sensibility Toward Cisplatin in Gastric Cancer Via the P53-P73/BIK Pathway. Cancers, 11, 1747. [Google Scholar] [CrossRef] [PubMed]
[26] Park, S.J., Kim, J.K., Bae, H.J., Eun, J.W., Shen, Q., Kim, H.S., Shin, W.C., Yang, H.D., Lee, E.K., You, J.S., Park, W.S., Lee, J.Y. and Nam, S.W. (2014) HDAC6 Sustains Growth Stimulation by Prolonging the Activation of EGF Receptor through the Inhibition of Rabaptin-5-Mediated Early Endosome Fusion in Gastric Cancer. Cancer Letters, 354, 97-106. [Google Scholar] [CrossRef] [PubMed]
[27] Fernández-Coto, D.L., Gil, J., Hernández, A., Herrera-Goepfert, R., Castro-Romero, I., Hernández-Márquez, E., Arenas-Linares, A.S., Calderon-Sosa, V.T., Sanchez-Aleman, M.Á., Mendez-Tenorio, A., Encarnación-Guevara, S. and Ayala, G. (2018) Quantitative Proteomics Reveals Proteins Involved in the Progression from Non-Cancerous Lesions to Gastric Cancer. Journal of Proteomics, 186, 15-27. [Google Scholar] [CrossRef] [PubMed]
[28] Zhang, S., Yang, Y, Huang, S.L., Deng, C., Zhou, S.Q., Yang, J., Cao, Y., Xu, L., Yuan, Y., Yang, J., Chen, G.X., Zhou, L., Lv, Y., Wang, L. and Zou, X.P. (2019) SIRT1 Inhibits Gastric Cancer Proliferation and Metastasis Via STAT3/MMP-13 Signaling. Journal of Cellular Physiology, 234, 15395-15406. [Google Scholar] [CrossRef] [PubMed]
[29] Hu, Y.W., Lin, J.H., Lin, Y., Chen, X.X., Zhu, G.B. and Huang, G.Y. (2019) Overexpression of SIRT4 Inhibits the Proliferation of Gastric Cancer Cells through Cell Cycle Arrest. Oncology Letters, 17, 2171-2176. [Google Scholar] [CrossRef] [PubMed]
[30] Lu, X., Yang, P.F., Zhao, X.R., Jiang, M.Z., Hu, S.J., Ouyang, Y.N., Zeng, L. and Wu, J. (2019) OGDH Mediates the Inhibition of SIRT5 on Cell Proliferation and Migration of Gastric Cancer. Experimental Cell Research, 382, Article ID: 111483. [Google Scholar] [CrossRef] [PubMed]
[31] 余亮, 江惠丽, 刘豪杰, 和韩玮. 褐藻多糖硫酸酯通过调控HDAC1基因的表达促进胃癌细胞凋亡[J]. 中国病理生理杂志, 2019, 35(6): 1075-1080.
[32] Colarossi, L., Memeo, L., Colarossi, C., Aiello, E., Iuppa, A., Espina, V., Liotta, L. and Mueller, C. (2014) Inhibition of Histone Deacetylase 4 Increases Cytotoxicity of Docetaxel in Gastric Cancer Cells. Proteomics—Clinical Applications, 8, 924-931. [Google Scholar] [CrossRef] [PubMed]

为你推荐